None
Quote | Bavarian Nordic R/I Ord (OTCMKTS:BVNKF)
Last: | $18.72 |
---|---|
Change Percent: | 0.0% |
Open: | $18.72 |
Close: | $18.72 |
High: | $18.72 |
Low: | $18.72 |
Volume: | 400 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bavarian Nordic R/I Ord (OTCMKTS:BVNKF)
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathwa...
2024-03-06 10:46:02 ET Bavarian Nordic A/S (BVNKF) Q4 2023 Earnings Conference Call March 06, 2024 08:00 AM ET Company Participants Rolf Sorensen - Vice President of Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel - Executiv...
Message Board Posts | Bavarian Nordic R/I Ord (OTCMKTS:BVNKF)
Subject | By | Source | When |
---|---|---|---|
Emylers: BVNKF Financials Monday, July 14, 2014 10:38:14 PM Bavarian Nordic A/S Data is unavailable | Emylers | investorshangout | 07/15/2014 2:38:15 AM |
Stock_Tracker: Latest Banarian Nordic Res (BVNKF) Headlines Bavarian Nordic's MVA-BN(R) Vaccine Plat | Stock_Tracker | investorshangout | 03/09/2014 9:02:28 AM |
chartguy89: BVNKF 18.25 Stock Charts $BVNKF 1 Month Chart | chartguy89 | investorshangout | 03/06/2014 10:46:15 AM |
Stock_Tracker: BVNKF Recent News Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Depar | Stock_Tracker | investorshangout | 03/03/2014 9:46:19 AM |
chartguy89: BVNKF Stock Charts Monday, February 24, 2014 at 3:09:03 AM $BVNKF Last: +1.60 | chartguy89 | investorshangout | 02/24/2014 8:09:15 AM |
News, Short Squeeze, Breakout and More Instantly...
Bavarian Nordic R/I Ord Company Name:
BVNKF Stock Symbol:
OTCMKTS Market:
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathwa...
Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination. A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a ...